Lifespan is a feasible endpoint for human clinical trials targeting aging in dogs, but not humans.

“the the challenge is i think the reason why this hasn't happened one rapamycin's off patent nobody's going to make money off of it and two there is a misplaced concern about side effects which we've already talked about it's just not reality that the risk is is significant at doses of rapamycin that would be tested so i think the real challenge though is identifying the right endpoints for a clinical trial in aging you're not going to do life span in people we can do it in dogs you're not going to do it in people i think we just have to accept that”